Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
16 avr. 2024 16h01 HE
|
Sentia Medical Sciences, Inc.
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have further extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX)...
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
14 févr. 2023 16h01 HE
|
Sentia Medical Sciences, Inc.
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at...
Sentia Medical Sciences and Neurocrine Biosciences Enter into Strategic Collaboration to Discover Novel CRF Peptides
26 avr. 2021 16h01 HE
|
Sentia Medical Sciences, Inc.
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have entered into a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed...
Sentia Medical Sciences Inc. Awarded Approximately $1.8 million Phase II Small Business Innovation Research (SBIR) Grant to Develop Astressins for the Treatment of Irritable Bowel Syndrome (IBS)
22 mai 2019 00h01 HE
|
Sentia Medical Sciences, Inc.
SAN DIEGO, May 22, 2019 (GLOBE NEWSWIRE) -- Sentia announced today that it has been awarded a phase II small business innovation research (SBIR) grant from the National Institute of Diabetes and...
Sentia Medical Sciences Inc. Appoints Dr. Yvette Taché as Chair of the Scientific Advisory Board and Announces Award of a Phase 1 Small Business Innovation Research (SBIR) Grant to Develop Astressins for the Treatment of Irritable Bowel Syndrome (IBS)
12 juin 2018 03h01 HE
|
Sentia Medical Sciences, Inc.
SAN DIEGO, June 12, 2018 (GLOBE NEWSWIRE) -- Sentia announced today the appointment of Dr. Yvette Taché, Ph.D. as Chair of the Scientific Advisory Board. Dr. Taché, Ph.D. is a Distinguished...
Sentia Medical Sciences Inc. Announces the Launch of a New Initiative in Stress-related Disorders Targeting Gastrointestinal and Endocrine Diseases
17 nov. 2017 03h01 HE
|
Sentia Medical Sciences, Inc.
SAN DIEGO, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Sentia announced today that it will bring to fruition several decades of academic research by developing a new generation of first in class drug...